Pacific Biosciences of California Inc (NASDAQ:PACB) price on Thursday, April 18, rose 4.29% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $1.46.
A look at the stock’s price movement, the close in the last trading session was $1.40. The beta value (5-Year monthly) was 1.83. Turning to its 52-week performance, $14.55 and $1.25 were the 52-week high and 52-week low respectively. Overall, PACB moved -59.89% over the past month.
Pacific Biosciences of California Inc’s market cap currently stands at around $397.53 million, with investors looking forward to this quarter’s earnings report slated for Apr 30, 2024 – May 06, 2024.
Revisions could be used as tool to get short term price movement insight, and for the company that in the past seven days was no upward and no downward review(s). Turning to the stock’s technical picture we see that short term indicators suggest on average that PACB is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
PACB’s current price about -55.50% and -67.00% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 18.12, while 7-day volatility ratio is 21.39% and 10.71% in the 30-day chart. Further, Pacific Biosciences of California Inc (PACB) has a beta value of 2.01, and an average true range (ATR) of 0.38.
If we refocus on Pacific Biosciences of California Inc (NASDAQ:PACB), historical trading data shows that trading volumes averaged 9.44 million over the past 3 months. The company’s latest data on shares outstanding shows there are 267.74 million shares.
The 6.08% of Pacific Biosciences of California Inc’s shares are in the hands of company insiders while institutional holders own 96.78% of the company’s shares. Current price change has pushed the stock -85.12% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the PACB stock continues to rise going into the next quarter.
